Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

SDĚLENÍ

Ministerstva xxxxxxxxxxxx věcí,

kterým xx xxxx a xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Xx. m. x. x x. 46/2008 Sb. x. x.

Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 1. xxxxx 2017 xxxx xxxxxxxxx ředitelkou XXXXXX xxxxxxxx xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx a xxxxx dopingu xxx xxx 2018 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx¹⁾.

X xxxxx xxxxxx Přílohy X xxxxxxxx souhlas Parlament Xxxxx republiky x xxxxxxxxx xxxxxxxxx podepsal xxxxxxx x xxxxxxx xxxx Přílohy X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x platnost v xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. ledna 2018. Pro Českou xxxxxxxxx xxxxxxxxx nové xxxxx Přílohy I x xxxxxxxx dne 5. června 2019.

Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx I v xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X xxxxxx xx 1. xxxxx 2017 x xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Xxxxxxxx xxxxx nového xxxxx Xxxxxxx X a xxxx xxxxxxx xx xxxxxxx xxxxxx se xxxxxxxxx xxxxxxxx.

XXXXXXX

XXXXXXXXXXXXX

XXXXXXXX

XXXXXXX XXXXXXXXXXXXX XXXXX

XXXXXX XXXXXXXXXX LÁTEK X XXXXX XXXXXXX XXX XXX 2018

XXXXXXXXXXX XXXXXXXX

Xxxxxxxxx xxxx Xxxxxxx xxxx xxxxxxxxx XXXX x xxxx xxxxxxxxxx x angličtině x xxxxxxxxxxxxx.

X xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx x francouzskou verzí xxxx xxxxxxxxxxx xxxxxxxx xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx xx 1. xxxxx 2018 

SEZNAM XXXXXXXXXX XXXXX X METOD XXXXXXX XXX ROK 2018

XXXXXXX ANTIDOPINGOVÝ KODEX

Platný xx 1. xxxxx 2018

XXXXX A XXXXXX XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx látky xxxxx xxxxxxxxxx xx "Specifické xxxxx" xxxxx xxxxx xx xxxxxx X1, X2, S4.4, X4.5 x S6(a) x Xxxxxxxxxx xxxxx X1, X2 x X3.

XXXXXXXX XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxx látka, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx pro xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (xxxx. léčiva x preklinickém xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx veterinární xxxxxxx), xx zakázána stále.

S1. XXXXXXXXXX LÁTKY

Anabolické látky xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):

(a) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-androst-1-en-3,17-dion);

1-androsteron (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17ß-ol);

drostanolon;

ethylestrenol (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (methyltrienolon (17ß-hydroxy-17α-methylestra-4,9,11-trien-3-on);

miboleron;

norboleton;

norethandrolon;

norklostebol;

oxabolon;

oxandrolon;

oxymesteron;

oxymetolon;

prostanozol (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-hydroxy-18α-homo-19-nor-17α-pregna-4,9,11-trien-3-on);

trenbolon (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-diol);

19-norandrostendion (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-hydroxyandrost-5-en-17-on);

testosteron;

a xxxxxx xxxxxxxxxx x xxxxxxx, xxxxxx, xxx xx x omezením xxxxx na ně:

5α-androstan-3α,17α-diol;

5α-androstan-3α,17ß-diol;

5α-androstan-3ß,17α-diol;

5α-androstan-3ß,17ß-diol;

5ß-androstan-3α,17ß-diol;

5α-androst-2-en-17-on;

androst-4-en-3α,17α-diol;

androst-4-en-3α,17ß-diol;

androst-4-en-3ß,17α-diol;

androst-5-en-3α,17α-diol;

androst-5-en-3α,17ß-diol;

androst-5-en-3ß,17α-diol;

4-androstendiol (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (androst-5-en-3,17-dion);

androsteron;

epi-dihydrotestosteron;

epitestosteron;

etiocholanolon;

3ß-hydroxy-5α-androstan-17-on;

7α-hydroxy-DHEA;

7ß-hydroxy-DHEA;

7-keto-DHEA;

19-norandrosteron;

19-noretiocholanolon.

2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM, např. xxxxxxx, XXX-4033, xxxxxxx x XXX140); xxxxxxx; xxxxxxx x zilpaterol, xxx xx s xxxxxxxx xxxxx xx xx.

Xxx účely xxxxxxx xxxx xxxxx: * "exogenní" xx xxxxxxxx x xxxxx, kterou tělo xxxxxxxx xxxxxxxxx neprodukuje. ** "xxxxxxxxx " se xxxxxxxx x xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxx.

X2. PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX LÁTKY X XXXXXXXX

Xxxxxxxxxxx xxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx podobnými biologickými xxxxxx xxxx zakázány:

1. Xxxxxxxxxxxxx (EPO) x xxxxxxxxxx ovlivňující xxxxxxxxxxx, xxxxxx, xxx ne x xxxxxxxx xxxxx xx xx:

1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx receptoru, např

darbepoetiny (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx XXX (EPO-Fc, xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)); EPO-mimetické xxxxxxxxxx a xxxxxx xxxxxxxxxx (xxxx. XXXX 530 x xxxxxxxxxxx).

1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx faktoru (HIF), xxxx.

xxxxx; xxxxxx; molidustat; xxxxxxxxxx (XX-4592); xenon.

1.3 Xxxxxxxxxx XXXX, xxxx.

X-11706.

1.4 Xxxxxxxxxx XXX - xxxx (TGF - β), xxxx.

xxxxxxxxxxxx; xxxxxxxxxxx.

1.5 Xxxxxxxx vrozeného xxxxxxxxx xxxxxxxxx. xxxx.

xxxxxx EPO; xxxxxxxxxxxxx XXX.

2. Xxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (XX) x xxxxxxxxxxxx xxxxxx (XX) a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx, x xxxx.

2.2 Kortikotropiny a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx.

2.3 Xxxxxxx xxxxxx (XX), jeho xxxxxxxxx x uvolňující xxxxxxx, včetně, xxx xx x xxxxxxxx xxxxx xx ně:

fragmenty xxxxxxxxx xxxxxxx, např. XXX-9604 x hGH 176-191; xxxxxx uvolňující xxxxxxx xxxxxx (XXXX) x xxxx analoga, xxxx. XXX-1295, xxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxxx a xxxxxxxx xxxxxxxx, xxxx. xxxxxxxxxx, ipamorelin x xxxxxxxxxxx; uvolňující peptidy xxxxxxxxx xxxxxxx (XXXX), xxxx. xxxxxxxxxxxx, GHRP-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, XXXX-5, XXXX-6 x xxxxxxxxx.

3. Xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxxxx, xxx xx s xxxxxxxx xxxxx xx xx:

xxxxxxxxxxxxx růstové xxxxxxx (XXXx);

xxxxxxxxxxxx xxxxxxx faktor (XXX);

xxxxxxxx podobný xxxxxxx xxxxxx-1 (XXX-1) a xxxx xxxxxxx

xxxxxxxxxx xxxxxxx xxxxxxx (XXX);

xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX);

xxxxxxxx- β4 x xxxx xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (VEGF).

Další xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx faktorů ovlivňující xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, šlach x xxxxxx, xxxxxx xxxxxxxx, využití energie, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx xxxxxxxxxx i xxxxxxxxxxxx xxxx-2 xxxxxxxx, xxxxxx xxxxx optických xxxxxxx, xxxx xxxxxxxx.

Xxxxxxxx (xxx xx s xxxxxxxx xxxxx na xx):

Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; reproterol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx jsou:

• inhalační xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx za 24 xxxxx x oddělených xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx xxxxx xxxxxxx 12 xxxxx po xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx dávka 54 xxxxxxxxxx za 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x přítomnost formoterolu x xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx považována xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální xxxxxxxx xxx způsoben xxxxxxxxxxxxx xxxxxx (x xxxxxxxx) xxxxx, xxx xxxx xxxxxxx xxxxxxxxx dávka.

S4. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx a metabolické xxxxxxxxxx:

1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (androstatriendion);

androsta-3,5-dien-7-17-dion (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), zahrnující:

Raloxifen;

tamoxifen;

toremifen, xxx ne s xxxxxxxx pouze xx xx.

3. Xxxxxxx antiestrogenní xxxxx zahrnující:

Cyklofenil;

fulvestrant;

klomifen, ale xx x xxxxxxxx xxxxx na xx.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx ne x omezením pouze xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (AMPK), např. XXXXX; a Xxxxxxxx Xxxxxxxxx xxxxx aktivovaného xxxxxxxxxxxxxx proliferátory (PPARδ), xxxx. 2-(2-xxxxxx-4-((4-xxxxxx-2-(4-(xxxxxxxxxxxxxxx)xxxxxx)xxxxxxx-5-xx)xxxxxxxxxx)xxxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516);

5.2 xxxxxxxx x mimetika xxxxxxxx;

5.3 xxxxxxxxx;

5.4 trimetazidin.

S5. XXXXXXXXX A XXXXXXXXX XXXXX

Xxxxxxxxxxx diuretika x xxxxxxxxx látky jsou xxxxxxxx, xxxxxx jako xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; xxxxxxxxxxxxxxx (např. xxxxxxxxxx podání albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx a xxxxxxxxx); xxxxxxxxxx, ale xx s omezením xxxxx na xx.

• Xxxxxxxxxxxx; xxxxxxxx; bumetanid; furosemid; xxxxxxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxx etakrynová; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx (např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx); xxxxxxxxxx x xxxxxxx (xxxx. xxxxxxxxx), xxx xx x xxxxxxxx xxxxx xx xx.

X xxxxxxxx:

• xxxxxxxxxxxx; pamabromu a xxxxxx xxxxxx inhibitorů xxxxxxxxxxxxxx (xxxx. xxxxxxxxxxx x brinzolamidu)

• Lokálního xxxxxx xxxxxxxxxxxx xxx zubní xxxxxxxxx

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (tj. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, metylefedrin a xxxxxxxxxxxxx) xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x xxxxxxxxxx nebo xxxxx xxxxxxxxx látkou, bude xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx, pokud Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) xx xxxx xxxxx xxxxx x té, xxxxx již xxxx xxxxxxx na xxxxxxxxxx xxxx xxxxx maskovací xxxxx.

XXXXXXXX XXXXXX

X1. MANIPULACE X KRVÍ A XXXXXXXX KOMPONENTAMI

Zakázané xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx krve xxxx červených xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx oběhového systému.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx hemoglobinové xxxxxxxx (xxxx. krevní náhražky xxxxxxxx xx xxxxxxxxxxx x mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx ne x omezením xxxxx xx xx. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx s xxxxxxxx komponentami xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx následující:

1. Xxxxxxxxx, nebo Pokus x Xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Vzorků xxxxxxxxxx při Dopingové xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx úpravu (xxxx. xxxxxxxxxx) moči, xxx ne x xxxxxxxx pouze na xx.

2. Nitrožilní xxxxxx x/xxxx xxxxxxx více xxx xxxxxx 100 xx za 12 xxxxx xxxxx infuzí xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx zákroků, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx metod.

M3. XXXXXX DOPING

Z důvodu xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx geneticky produkovaných xxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxxx sekvencí xxxxxx x/xxxx x transkripční xxxx epigenetické xxxxxxxx xxxxxx xxxxxxx.

3. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX A XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 xx X5 a X1 až X3 xxxxxxxxx xxxx

xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. x- a X-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (d-);

mezokarb;

modafinil;

norfenfluramin;

p-metylamfetamin;

prenylamin;

prolintan.

Stimulancium, xxxxx xxxx výslovně xxxxxxx x xxxxx odstavci, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (ale xx x omezením xxxxx xx xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx x jeho xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxx;

xxxxx**;

xxxxxxx x xxxx xxxxxxx (xxxx. xxxxxxxx, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (metylsynefrin);

pemolin;

pentetrazol;

propylhexedrin;

pseudoefedrin*****;

selegilin;

sibutramin;

strychnin;

tenamfetamin (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x další xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx x případě xxxxxx xxxxxxxx/xxxxxx použití x stimulancií xxxxxxxxxx xx Monitorovacího xxxxxxxx xxx rok 2018*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, nikotin, xxxxxxxxx x synefrin: Xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2018 a xxxxxx xxxxxxxxxx za Xxxxxxxx xxxxx.

** Xxxxx: xx xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 mikrogramů x 1 xx xxxx.

*** Xxxxxxx a methylefedrin: xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx xxxx.

**** Xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxx xxx xxxxxxxx xxxxxx, např. xxxxx, xxxx xxxxxxxx nebo xxxx xxxxxx xxxxxxxx x lokálními xxxxxxxxxx.

***** Xxxxxxxxxxxxx: xx zakázán, xxxxx jeho xxxxxxxxxxx x xxxx xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx a xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx kanabinoidy xxxx xxxxxxxx:

• Xxxxxxxx xxxxxxxxxxx, xxxx. xxxxx, xxxxxx x marihuana.

• Syntetické kanabinoidy, xxxx. delta9-tetrahydrokanabinol (XXX) x xxxxxxx kanabimimetika.

Kromě: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, rektálně, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.

Xxxxxx, xxx xx s xxxxxxxx xxxxx xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX XXXXXXXX X&xxxx;XXXXXXXX XXXXXXXX

X1. BETA-BLOKÁTORY

Beta-blokátory jsou xxxxxxxx pouze x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx, x xxx xx xx xxxxxxxx x Xxxx soutěž.

• Automobilový xxxxx (XXX)

• Xxxxxxxx (všechny xxxxxxxxxx) (XXXX)

• Xxxx (IGF)

• Lukostřelba (XX)*

• Xxxxxxxx (XXX) - xxxxx xx lyžích x xxxxxxxxxxx xxxxxxxx-xxxxx x U-rampa, x xxxxxxxxx U-rampa a "xxx xxx"

• Xxxxxxxx sporty (xxxxxxxxx xxxxxxxx) (XXXX) x xxxxxxxxxxxx xxxxxxxxxx xxxx x ploutvemi xxxx xxx xxxxxxx, xxxxxxxxx apnoe x xxxxxxxxx xxxx xxx xxxxxxx, xxxx immersion, xxxx blue, xxxxxxxxxxxx, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx xx terč x variabilní xxxx.

• Xxxxxxx (XXXX, IPC)*

• Šipky (XXX)

* Xxxxxxxx xxxx Mimo xxxxxx

Xxxx-xxxxxxxxx zahrnují xxxxxxxxxxx xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx xx s xxxxxxxx xxxxx na xx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 36/2019 Xx. x. x. nabyl účinnosti xxxx 26.7.2019.

Xxxxxx xxxxxxx x. 36/2019 Xx. x. s. byl xxxxxx xxxxxxx xxxxxxxxx č. 32/2023 Sb. m. s. x xxxxxxxxx xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx, přijatá xxx 19. xxxxx 2005 x Paříži, xxxx xxxxxxxxx v xxxxxxxxx xxxxx a x xxxxxxxxx do xxxxxxx xxxxxx pod č. 58/2007 Sb. m. s.

Xxxx xxxxx xxxxxxxx Úmluvy xx xxxxxxx xxxxxx xxxx xxxxxxxxx pod č. 46/2008 Sb. m. s.